ML-12 Clinical impact and management of skin-related disorders during treatment of relapsed PCNSL by tirabrutinib

BACKGROUNDS: Tirabrutinib is a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, approved by the Japanese Pharmaceutical and Medical Devices Agency (PMDA) for relapsed and refractory PCNSL in March 2020. Skin-related disorder (SRD)s are the most prevalent adverse events in tirabrutinib, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Nobuyoshi, Kobayashi, Keiichi, Saito, Kuniaki, Onoda, Ryo, Seiya, Yosuke, Suzuki, Saki, Yamagishi, Yuki, Nakatomi, Hirofumi, Shiokawa, Yoshiaki, Nagane, Motoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648233/
http://dx.doi.org/10.1093/noajnl/vdab159.091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648233/
http://dx.doi.org/10.1093/noajnl/vdab159.091

Ejemplares similares